BIOLASE

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

BIOLASE reports strong Q1 performance, eyes profitability through market growth

BIOLASE's Q1 2024 earnings reflect a robust performance with growth in sales and improved financial metrics. The company's strategic focus on accelerating dental laser adoption and operational enhancements position it well for future success. While challenges exist in achieving profitability, BIOLASE's opportunities in the dental market and growth initiatives offer a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1984 and is headquartered in Lake Forest, CA.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of September 30th, about a month before the elections. In this article we look at what those investors think of Biolase Inc (NASDAQ:BIOL).

Do Hedge Funds Love Biolase Inc (BIOL)?

FOOTHILL RANCH, Calif., Nov. 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020. President and CEO Todd Norbe...

BIOLASE to Participate at the Benchmark Company Discovery One on One Investor Conference on November 18, 2020

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q3 2020 Results - Earnings Call Transcript

FOOTHILL RANCH, Calif., Nov. 5, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2020 financial and operating results on Thursday, November 12, 2020 after the close of the U.S. financial markets and...

BIOLASE, Inc. to Report Third Quarter 2020 Results on November 12, 2020

FOOTHILL RANCH, Calif., Oct. 27, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has made available an updated corporate presentation and business summary overview on M-Vest.com. The Company plans to provide regular updates...

BIOLASE Announces Launch On M-Vest

FOOTHILL RANCH, Calif., Oct. 14, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced unaudited preliminary revenue results for the third quarter ended September 30, 2020. The Company expects to report third quarter revenue in the range of...

BIOLASE Announces Preliminary Third Quarter Revenue Results; Reopening Of Dental Practices Drives Sequential Revenue Growth

FOOTHILL RANCH, Calif., Sept. 11, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE To Present At H.C. Wainwright's 22nd Annual Global Investor Conference

FOOTHILL RANCH, Calif., Aug. 18, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE Regains Nasdaq Compliance For Minimum Stockholder Equity

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q2 2020 Results - Earnings Call Transcript

FOOTHILL RANCH, Calif., Aug. 13, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE Reports Second Quarter 2020 Financial Results

FOOTHILL RANCH, Calif., Aug. 6, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE, Inc. to Report Second Quarter 2020 Results on August 13, 2020

IRVINE, Calif., July 22, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE Announces Closing Of Oversubscribed Rights Offering

IRVINE, Calif., July 16, 2020 /PRNewswire/ -- BIOLASE, Inc.

BIOLASE Announces Expiration Of Oversubscribed Rights Offering

IRVINE, Calif., July 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced data published in the Journal of Periodontology from a clinical trial conducted at The McGuire Institute™. Designed to meet the stringent American Association of...

Landmark Head-to-Head Study Published in Journal of Periodontology Concludes That BIOLASE REPAIR® Perio Protocol is Superior for Procedure Time and Patient-Reported Outcomes

IRVINE, Calif., July 9, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that BIOLASE CEO Todd Norbe has been invited to participate in a panel discussion on Re-Engaging Medical Practices in an Era of COVID-19, presented by Maxim Group...

BIOLASE to Present at COVID-19 Webinar Hosted by Maxim Group on July 16, 2020

IRVINE, Calif., July 2, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, today announced that the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights...

BIOLASE, Inc. Announces Commencement of Rights Offering Subscription Period

IRVINE, Calif., June 22, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. Stockholders of record...

BIOLASE, Inc. Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

IRVINE, Calif., June 11, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the closing on June 10, 2020 of its previously announced registered direct offering of approximately $6.9 million of its common stock in a registered direct...

BIOLASE, Inc. Announces Closing of $6.9 Million Registered Direct Offering Priced At-The-Market

IRVINE, Calif., June 8, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $6.9 million of its common stock in a registered...

BIOLASE, Inc. Announces Pricing of $6.9 Million Registered Direct Offering Priced At-The-Market

BIOLASE Inc (BIOL) CEO Todd Norbe on Q1 2020 Results - Earnings Call Transcript

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q4 2019 Results - Earnings Call Transcript

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q3 2019 Results - Earnings Call Transcript

BIOLASE, Inc. (BIOL) CEO Todd Norbe on Q2 2019 - Earnings Call Transcript

DexCom

Haemonetics

Orthofix International

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Will MedTech Ease Investors' Concern & Outperform? 4 Picks

Biolase's (BIOL) CEO Todd Norbe on Q1 2019 Results - Earnings Call Transcript

News for BIOLASE Stock (BIOL)